ICOS to Participate in the UBS Global Life Sciences Conference
September 14 2006 - 8:00PM
Business Wire
ICOS Corporation (Nasdaq:ICOS) announced today that it will
participate in the UBS Global Life Sciences Conference on Tuesday,
September 26, 2006. The presentation, which may include discussions
of financial guidance and future plans, will be webcast. -0- *T UBS
Global Life Sciences Conference Presentation Date: September 26,
2006 Time: 10:00 a.m. Eastern Time Speaker: Paul N. Clark,
Chairman, President and CEO A webcast of this ICOS presentation
will be available in real-time and a replay will be available
through October 3, 2006. The webcast can be accessed through the
ICOS Web site, www.icos.com, Investor -- Events section. *T
Additional information on ICOS, including past press releases, is
also available at www.icos.com. About ICOS Corporation: ICOS
Corporation, a biotechnology company headquartered in Bothell,
Washington, is dedicated to bringing innovative therapeutics to
patients. Through Lilly ICOS LLC, ICOS is marketing its first
product, Cialis(R) (tadalafil), for the treatment of erectile
dysfunction. ICOS is working to develop treatments for serious
unmet medical needs such as benign prostatic hyperplasia,
hypertension, pulmonary arterial hypertension, cancer and
inflammatory diseases. This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements involve risks
and uncertainties that could cause ICOS' results and the timing of
certain events to differ materially from those discussed in the
forward-looking statements, including risks associated with product
commercialization, manufacturing activities, clinical development,
regulatory approvals, intellectual property claims and litigation
and other risks detailed in ICOS' latest Quarterly Report on Form
10-Q and its other SEC filings.
Icos (NASDAQ:ICOS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Icos (NASDAQ:ICOS)
Historical Stock Chart
From Nov 2023 to Nov 2024